RxDoctor Payments Data

Marlene Whitbeck

Nurse Practitioner · New York, NYNPI 1578898409

Payments from drug & device makers

$1,029in general payments, 2019–2025

Across 23 payments — averaging $44.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$259
  • Acadia Pharmaceuticals Inc$235
  • Otsuka America Pharmaceutical, Inc.$157
  • Axsome Therapeutics, Inc.$125
  • Neurocrine Biosciences, Inc.$116
  • Sanofi-aventis U.S. LLC$59
  • plus $78 from 3 others

What the payments were for

  • Food & beverage$1,029100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,029 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$34,410
Medicare patients
103
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$20,334
OzempicSemaglutide13$13,343
TrulicityDulaglutide22$11,684
Xtampza ErOxycodone Myristate26$6,611
Tresiba Flextouch U-100Insulin Degludec15$4,660
Divalproex Sodium ErDivalproex Sodium11$3,082
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$2,919
Admelog SolostarInsulin Lispro30$2,861
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$2,464
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc18$1,835
Morphine Sulfate ErMorphine Sulfate16$1,428
Carbamazepine ErCarbamazepine23$1,207
FenofibrateFenofibrate Nanocrystallized18$1,142
Potassium Chloride28$1,060
Morphine Sulfate48$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$33$11,68422 claims
Sanofi-aventis U.S. LLCLantus$59$78711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →